CVS trades at a forward multiple that screams cheap, yet the street's already bullish and our model runs even hotter. Before you trust either read, there are a few risks that could turn this setup into a trap.
CVS Health (CVS) concluded the recent trading session at $94.43, signifying a -1.17% move from its prior day's close.
CVS Health's Health Services arm is gaining from pharmacy strength and improving care delivery, with robust new sales and clinic economics supporting growth.
CVS is benefiting from pharmacy growth, AI investments and a discounted valuation, but reimbursement pressure and regulatory scrutiny remain key risks.
CVS Health trades at a discounted 12x forward P/E versus peers, despite robust business momentum and integrated healthcare assets. Q2 2026 saw 7% YoY revenue growth to $106B and 35% adjusted operating income growth, signaling a turnaround in earnings power. Aetna margin restoration, specialty pharmacy growth, and GLP-1 expansion offset risks from elevated medical costs and regulatory headwinds.
CVS Health NYSE: CVS executives said the company is seeing improved momentum across its insurance, pharmacy, care delivery and balance-sheet priorities, while maintaining a cautious outlook on healthcare cost trends and several 2027 headwinds.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CVS Health's strong cash generation, higher operating cash flow outlook and disciplined capital deployment support continued deleveraging in 2026.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.